Soliris generated $2.5 billion in 2024 sales, an 18% decline from the prior year. To offset the declines expected from biosimilar competition, AstraZeneca has for years been working to transition ...

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition.

AstraZeneca’s (AZN ... Phase III trial which were presented during a Presidential Symposium at the 2024 European Society for Medical Oncology, ESMO. In the trial, patients were treated with ...

AstraZeneca saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, including the European approval of DATROWAY for breast cancer treatment and ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ ... a surprise was the UK economy going up by 0.1% in Q4 2024, a welcome reprieve from the sodden economic outlook ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

BNP Paribas Exane initiated coverage of AstraZeneca (AZN) with an Outperform rating and $75 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter ...

The University of Virginia has tapped an executive at AstraZeneca, one of the world’s largest pharmaceutical companies, to head its future Manning Institute of Biotechnology. The $350 million ...

Tagrisso generated USD6.6 billion in global revenue in 2024 and accounted for 12% of AstraZeneca’s total revenue, making it the company’s second-highest revenue contributor and a core product ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

Compensation in sectors that saw the largest year-over-year increases can be attributed to across-the-board salary adjustments, retroactive payments made in the 2024 calendar year and the most recent ...

Today's announcement could potentially add to a string of bad tariff news that has cost Roche 10.9%, Lilly 14%, and AstraZeneca stock 14.4% over the past week. Still, it remains to be seen ...